Innovations & Thérapeutiques en Oncologie
MENU17th edition of the International Congress on Targeted Anti-Cancer Therapies (TAT) Volume 5, issue 3, May-June 2019
Authors
1 Gustave Roussy
Service d’innovations thérapeutiques et d’essais précoces
114, rue Edouard Vaillant
94800 Villejuif
France
Service d’innovations thérapeutiques et d’essais précoces
114, rue Edouard Vaillant
94800 Villejuif
France
* Tirés à part
- Key words: immunotherapy, early clinical trials, biomarkers
- DOI : 10.1684/ito.2019.0168
- Page(s) : 177-81
- Published in: 2019
This 17th edition featured many high-quality presentations in the field of innovative cancer therapy. The development of combination trials and their rational basis was, once again, the subject of debate. The constantly growing number of these trials throughout 2016 has rendered the landscape for therapeutic trials more complex. Several successes and failures were highlighted during this congress, which took stock of the various results from 2018 and the outlook for 2019.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License